22nd Century Group Inc (NYSE:XXII) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price target of $3.50 for the company, according to Zacks. Zacks has also assigned 22nd Century Group an industry rank of 105 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research cut 22nd Century Group from a “hold” rating to a “sell” rating in a report on Tuesday.
22nd Century Group (NYSE XXII) opened at 2.68 on Wednesday. 22nd Century Group has a 52 week low of $0.81 and a 52 week high of $2.84. The company’s market cap is $275.40 million. The stock has a 50 day moving average of $2.10 and a 200 day moving average of $1.57.
In related news, VP Michael Robert Moynihan sold 29,532 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $2.00, for a total value of $59,064.00. Following the completion of the sale, the vice president now directly owns 917,220 shares of the company’s stock, valued at approximately $1,834,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Institutional investors have recently made changes to their positions in the company. Virtu KCG Holdings LLC increased its holdings in 22nd Century Group by 300.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 126,106 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 94,650 shares during the last quarter. Northern Trust Corp boosted its stake in 22nd Century Group by 22.3% in the 2nd quarter. Northern Trust Corp now owns 133,797 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 24,401 shares during the period. National Asset Management Inc. boosted its stake in 22nd Century Group by 13.7% in the 1st quarter. National Asset Management Inc. now owns 172,000 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 20,700 shares during the period. Finally, Vanguard Group Inc. boosted its stake in 22nd Century Group by 17.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,894,322 shares of the biotechnology company’s stock worth $5,065,000 after purchasing an additional 432,450 shares during the period.
WARNING: This report was published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.thestockobserver.com/2017/09/13/zacks-22nd-century-group-inc-xxii-given-3-50-consensus-target-price-by-brokerages.html.
About 22nd Century Group
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for 22nd Century Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.